论文部分内容阅读
目的:观察绝经过渡期功血患者刮宫后行曼月乐与米非司酮间断给药对子宫内膜厚度、性激素的影响。方法:将2013年2月~2015年6月来我院治疗绝经过渡期功血的患者104例,按照完全随机的原则将其均分为观察组和对照组;刮宫术后5天,观察组行曼月乐置入治疗,对照组给予米非司酮间断口服治疗;观察两组患者的临床疗效,治疗前后子宫内膜厚度、月经量、血红蛋白浓度及性激素变化情况,不良反应发生率。结果:观察组的临床有效率(88.46%)显著高于对照组(59.62%),差异具体统计学意义。治疗后两组患者的子宫内膜厚度、月经量、血红蛋白浓度、FSH、E2、PRL、LH、P均有改善,但观察组患者各项指标的改善情况均显著优于对照组,差异具有统计学意义。对照组不良反应发生率(11.54%)显著高于观察组(42.31%),差异具有统计学意义。结论:曼月乐和米非司酮间断给药治疗方式治疗围绝经期功血均具有一定的临床疗效,其中曼月乐的临床疗效更加显著,不良反应发生率低,安全性高,值得临床上推广。
Objective: To observe the effects of Mirena and Mifepristone intermittent administration on endometrial thickness and sex hormones after curettage in patients with dysfunctional uterine bleeding during menopause. Methods: From February 2013 to June 2015 in our hospital for treatment of 104 cases of menopausal transitional dysfunctional uterine bleeding in accordance with the principle of completely random to be divided into observation group and control group; 5 days after curettage, the observation group The patients in control group were treated with intermittent oral administration of mifepristone. The clinical curative effect, endometrial thickness, menstrual flow, hemoglobin concentration, sex hormones and incidence of adverse reactions before and after treatment were observed. Results: The clinical effective rate in the observation group (88.46%) was significantly higher than that in the control group (59.62%), the difference was statistically significant. After treatment, the endometrial thickness, menstrual flow, hemoglobin concentration, FSH, E2, PRL, LH, P in both groups were improved, but the improvement of each index in the observation group was significantly better than the control group, the difference was statistically significant Significance of learning. The incidence of adverse reactions in the control group (11.54%) was significantly higher than the observation group (42.31%), the difference was statistically significant. Conclusion: Mirena and intermittent administration of mifepristone treatment of perimenopausal uterine bleeding have some clinical efficacy, including the clinical efficacy of Mirena more significant, low incidence of adverse reactions, high safety, it is worth clinical On the promotion.